56.58
+5.28%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alpa Laboratories
Its shares trade on NSE under the ticker ALPA.NS. It has been listed since 1 August 2007. In the fiscal year to 31 March 2025, it reported revenue of ₹1.12bn and net income of ₹195.0m. At that date it held total assets of ₹2.23bn and shareholders' equity of ₹1.71bn.
Alpa Laboratories Ltd. is a pharmaceutical holding company, which engages in the manufactures of drugs and chemicals. The company is headquartered in Indore, Madhya Pradesh. The company went IPO on 2007-08-01. The firm is engaged in manufacturing pharmaceutical finished dosage forms. Its product range includes a variety of generic and over the counter (OTC) drugs in various finished dosage forms for both human and veterinary use. For human use it offers capsules such as Ampicillin Capsule IP/BP, Amoxycillin Trihydrate Capsule IP/BP, Cloxacillin Capsules IP/BP and Piroxicam Capsules IP BP; creams, gels and ointments, which include Lidocaine Hydrochloride Jelly IP/USP, Nitrofurazone Cream USP, Miconazole Cream IP/BP and Clobetasole Ointment/Cream BP; ear and eye drops, such as Benzylpenicillin Inj. IP/BP and Benzathine Penicillin Inj. IP/BP, and tablets, such as Albendazole Tablet IP/USP, Paracetamol Tablet IP/BP and Tinidazole Tablets IP/BP. Its veterinary products include boluses, such as Alpamin Bolus and Alpazole Bolus, and injections, such as Atropine Inj. B.Vet.C and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Aug 2007
- Employees
- 318
- Website
- alpalabs.in ↗
Leadership
Pay as last reported
- Mr. Purushottam PatelChairman of the Board₹2.7m
- Jayesh PatelChief Executive Officer
- Bakulesh ShahChief Financial Officer, since 2014
- Mr. Paresh ChawlaManaging Director, Director
- Mahendra ChawlaWhole-Time Director, since 1997₹2.7m
- Pravin ShahWhole Time Director, since 1997₹2.5m
- Mr. Shitul ShahAdditional Director, since 2023
- Shashi JainWoman Director
- Devendra BahetiNon-Executive Independent Director
- Mr. Saket BahetiAdditional Non-Executive Independent Director
- Mrs. Jyoti JainAdditional Non-Executive Independent Director
- Mrs. Pratibha LunawatAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alpa Laboratories Ltd. manufactures Ampicillin Capsule IP/BP for human use in Indore, India.
- The company produces Miconazole Cream IP/BP for veterinary and human applications.
- Alpa Laboratories Ltd. offers Paracetamol Tablet IP/BP as a key product in the pharmaceutical sector.
Weaknesses
- Alpa Laboratories Ltd. has 318 employees, which is a small workforce for a pharmaceutical company.
- The company's product range includes only generic drugs without branded products.
- Alpa Laboratories Ltd. does not have a global presence beyond India.
Opportunities
- Alpa Laboratories Ltd. can expand its OTC drug offerings in the Indian market.
- The company can leverage its veterinary product line for growth in animal health.
- Alpa Laboratories Ltd. can target the growing demand for generic drugs in India.
Threats
- Alpa Laboratories Ltd. faces competition from larger pharmaceutical firms in India.
- The company's reliance on the Indian market limits its growth potential.
- Regulatory changes in the Indian pharmaceutical sector could impact operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.